(0.00%) 5 478.25 points
(-0.02%) 38 812 points
(0.03%) 19 928 points
(0.27%) $80.55
(1.15%) $2.82
(0.08%) $2 330.90
(-0.46%) $29.26
(-0.13%) $969.60
(0.03%) $0.932
(-0.11%) $10.64
(0.09%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States...
Stats | |
---|---|
Šios dienos apimtis | 912 229 |
Vidutinė apimtis | 537 515 |
Rinkos kapitalizacija | 435.08M |
EPS | $-0.430 ( Q4 | 2024-05-13 ) |
Kita pelno data | ( $-0.0600 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-4.35 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0210 (0.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-07 | Tourangeau Greg | Sell | 236 | Common Stock |
2024-03-18 | Horn Patrick Taylor | Buy | 400 000 | Stock Option (right to buy) |
2024-03-18 | Horn Patrick Taylor | Sell | 0 | No securities are beneficially owned |
2024-03-08 | Tourangeau Greg | Sell | 4 884 | Common Stock |
2024-03-04 | Sapir Alex | Buy | 43 360 | Common Stock |
INSIDER POWER |
---|
20.36 |
Last 98 transactions |
Buy: 8 691 029 | Sell: 9 091 582 |
Tūris Koreliacija
Fulcrum Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
GRPN | 0.894 |
RLMD | 0.892 |
CSX | 0.885 |
NRBO | 0.884 |
MORF | 0.882 |
ORMP | 0.882 |
ALLO | 0.88 |
CRSP | 0.868 |
SGMO | 0.864 |
PTH | 0.86 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Fulcrum Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Fulcrum Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $2.81M |
Bruto pelnas: | $633 000 (22.57 %) |
EPS: | $-1.590 |
FY | 2023 |
Pajamos: | $2.81M |
Bruto pelnas: | $633 000 (22.57 %) |
EPS: | $-1.590 |
FY | 2022 |
Pajamos: | $6.34M |
Bruto pelnas: | $3.93M (61.94 %) |
EPS: | $-2.35 |
FY | 2021 |
Pajamos: | $19.16M |
Bruto pelnas: | $19.16M (100.00 %) |
EPS: | $-2.29 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.